Title:
PYRIDINE DERIVATIVE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/045960
Kind Code:
A1
Abstract:
A pyridine derivative and use thereof. The compound has an obvious inhibitory effect on the activity of KRAS and PI3K proteins, can be used as a KRAS and/or PI3K protein inhibitor, and can be used for preparing a drug for treatment of diseases such as KRAS or PI3K protein-mediated cancer. The compound has an extremely strong inhibitory effect on a KRAS G12C inhibitor drug-resistant cancer cell, e.g. AMG-510, and has a wide application prospect.
More Like This:
| WO/2019/217421 | SMALL MOLECULE INHIBITORS OF CDK12/CDK13 |
| JP2014129378 | QUINOLINONE DERIVATIVE AS TYROSINE KINASE INHIBITOR |
| WO/2007/110337 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS |
Inventors:
CHEN SHOUJUN (CN)
QIANG XIAOMING (CN)
DING ZHAO (CN)
XIONG YONG (CN)
WANG HAIBO (CN)
LIU KE (CN)
LIU MINGDENG (CN)
QIANG XIAOMING (CN)
DING ZHAO (CN)
XIONG YONG (CN)
WANG HAIBO (CN)
LIU KE (CN)
LIU MINGDENG (CN)
Application Number:
PCT/CN2022/120154
Publication Date:
March 30, 2023
Filing Date:
September 21, 2022
Export Citation:
Assignee:
SICHUAN HUIYU PHARMACEUTICAL CO LTD (CN)
SICHUAN HUIYU SEACROSS PHARMACEUTICAL TECH CO LTD (CN)
SICHUAN HUIYU SEACROSS PHARMACEUTICAL TECH CO LTD (CN)
International Classes:
C07D401/14; A61K31/517; A61P35/00; C07D239/72; C07D403/14; C07D471/04
Domestic Patent References:
| WO2016044772A1 | 2016-03-24 | |||
| WO2014160177A2 | 2014-10-02 | |||
| WO2017070256A2 | 2017-04-27 | |||
| WO2016164675A1 | 2016-10-13 | |||
| WO2016168540A1 | 2016-10-20 | |||
| WO2018119183A2 | 2018-06-28 | |||
| WO2018206539A1 | 2018-11-15 | |||
| WO2020216190A1 | 2020-10-29 |
Foreign References:
| US20180118757A1 | 2018-05-03 | |||
| CN106488910A | 2017-03-08 | |||
| CN103987699A | 2014-08-13 | |||
| CN104302647A | 2015-01-21 | |||
| CN110022878A | 2019-07-16 |
Other References:
NAT REV DRUG DISCOV, vol. 13, 2014, pages 828 - 851
NATURE, vol. 503, 2013, pages 548 - 551
SCIENCE, vol. 351, 2016, pages 604 - 608
CANCER DISCOV, vol. 6, 2016, pages 316 - 29
MATTHEW, R. JANESYI LIU ET AL., CELL, vol. 172, 2018, pages 578 - 589
XIE, J.Y ET AL., NATURE, vol. 577, 2020, pages 421 - 425
ADACHI, Y ET AL., CLIN CANCER RES, 8 September 2020 (2020-09-08)
NATURE, vol. 503, 2013, pages 548 - 551
SCIENCE, vol. 351, 2016, pages 604 - 608
CANCER DISCOV, vol. 6, 2016, pages 316 - 29
MATTHEW, R. JANESYI LIU ET AL., CELL, vol. 172, 2018, pages 578 - 589
XIE, J.Y ET AL., NATURE, vol. 577, 2020, pages 421 - 425
ADACHI, Y ET AL., CLIN CANCER RES, 8 September 2020 (2020-09-08)
Attorney, Agent or Firm:
MERITS IP LTD. (CN)
Download PDF: